Journal of Preventive Medicine

Precision medicine in sepsis

9^th Edition of International Conference on Preventive Medicine & Public Health
July 16-17, 2018 London, UK

Haibo Zhang

St. Michael�s Hospital - University of Toronto, Canada

Keynote: J Prev Med

DOI: 10.21767/2572-5483-C1-001

Abstract

Sepsis is a life-threatening condition that results in 30% mortality in critically ill patients, and many survivors are with poor quality of life due to long-lasting impact of sepsis on functional and cognitive limitations. There are no proven specific pharmacotherapies for sepsis, and thus new approaches are urgently needed. As our ability to identify the clinical and biological heterogeneity in human sepsis expands, precision medicine may hold the key to therapeutic breakthroughs. Recent advances in molecular diagnostics and omics approaches have great impact on precision medicine that is rapidly expanding. However, precision medicine should not be limited to using just omics based data. The key common approach is the recognition that disease heterogeneity may have important implications for clinical outcomes and for the effectiveness of novel therapies.

Biography

Haibo Zhang has completed his PhD from Free University of Brussels, Belgium. He is a Full-Professor of Anaesthesia, Critical Care Medicine and Physiology at the Universityof Toronto, Canada. He is the Head of the Theme of Biomaterial, Organ Injury and Repair, Institute of Biomedical Engineering Science and Technology (iBEST), a premier research organization operated by St. Michael’s Hospital and Ryerson University, Toronto, Canada. He has published more than 200 papers in reputed journals and has been serving as an Editorial Board Member of repute journals.

E-mail: zhangh@smh.ca